文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急性呼吸窘迫综合征的早期神经肌肉阻滞

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome.
PubMed 文献 · N Engl J Med · 2019-05-19
一句话结论在中重度ARDS且采用高PEEP策略的患者中,早期连续输注顺阿曲库铵48小时与常规较轻镇静相比,90天院内死亡率无显著差异(42.5% vs 42.8%)。

该研究纳入1006例中重度ARDS患者(PaO2/FiO2<150 mmHg且PEEP≥8 cmH2O),随机分为48小时连续输注顺阿曲库铵联合深镇静组(干预组)或常规治疗无神经肌肉阻滞且较轻镇静目标组(对照组),两组均采用相同机械通气策略包括高PEEP。主要终点为90天院内全因死亡。试验在第二次中期分析时因无效而停止。90天时干预组死亡213例(42.5%),对照组死亡216例(42.8%),组间差异-0.3个百分点(95%CI -6.4至5.9;P=0.93),无显著差异。干预组住院期间活动更少且心血管不良事件更多。

要点

  • 中重度ARDS(PaO2/FiO2<150 mmHg且PEEP≥8 cmH2O)患者早期48小时连续输注顺阿曲库铵与常规较轻镇静相比,90天院内死亡率无显著差异(42.5% vs 42.8%,P=0.93)。
  • 干预组501例中488例(97.4%)在随机后48小时内开始连续输注顺阿曲库铵,中位输注时长47.8小时,中位剂量1807 mg;对照组505例中86例(17.0%)接受了神经肌肉阻滞剂,中位剂量38 mg。
  • 干预组住院期间身体活动更少,心血管不良事件更多。
  • 3、6、12个月评估的终点无一致组间差异。
  • 试验在第二次中期分析时因无效而停止。

适用人群与场景

  • 中重度ARDS患者,定义为动脉血氧分压与吸入氧浓度比值<150 mmHg且呼气末正压(PEEP)≥8 cmH2O。
  • 患者在ARDS发病早期入组(中位发病后7.6小时)。

诊断标准与关键阈值

  • 中重度ARDS诊断标准:PaO2/FiO2<150 mmHg且PEEP≥8 cmH2O。

处置流程与药物剂量

  • 干预组:随机后48小时内开始连续输注顺阿曲库铵,中位输注时长47.8小时,中位剂量1807 mg,同时辅以深镇静。
  • 对照组:常规治疗不常规使用神经肌肉阻滞,采用较轻镇静目标;对照组中17.0%(86/505)接受了神经肌肉阻滞剂,中位剂量38 mg。
  • 两组均采用相同的机械通气策略,包括高PEEP策略。
  • 主要终点为90天院内全因死亡。

研究设计与关键结果

  • 研究类型:随机对照试验;样本量1006例;人群为中重度ARDS早期患者(中位发病后7.6小时)。
  • 干预与对照:48小时连续输注顺阿曲库铵联合深镇静 vs 常规治疗无神经肌肉阻滞且较轻镇静目标,两组均采用高PEEP策略。
  • 主要终点:90天院内全因死亡,干预组213例(42.5%)vs 对照组216例(42.8%),组间差异-0.3个百分点(95%CI -6.4至5.9;P=0.93),无显著差异。
  • 关键次要终点:干预组住院期间身体活动更少,心血管不良事件更多;3、6、12个月评估的终点无一致组间差异。
  • 试验在第二次中期分析时因无效而停止。

证据类型、等级与局限

  • 证据类型:随机对照试验。
  • 试验因无效在第二次中期分析时停止。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于中重度ARDS(PaO2/FiO2<150 mmHg且PEEP≥8 cmH2O)且采用高PEEP策略的患者,早期连续48小时输注顺阿曲库铵并未显著降低90天院内死亡率,且干预组身体活动更少、心血管不良事件更多。

指南或共识出处

  • ROSE ClinicalTrials.gov number, NCT02509078; funded by the National Heart, Lung, and Blood Institute.

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The benefits of early continuous neuromuscular blockade in patients with acute respiratory distress syndrome (ARDS) who are receiving mechanical ventilation remain unclear.

METHODS: We randomly assigned patients with moderate-to-severe ARDS (defined by a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of <150 mm Hg with a positive end-expiratory pressure [PEEP] of ≥8 cm of water) to a 48-hour continuous infusion of cisatracurium with concomitant deep sedation (intervention group) or to a usual-care approach without routine neuromuscular blockade and with lighter sedation targets (control group). The same mechanical-ventilation strategies were used in both groups, including a strategy involving a high PEEP. The primary end point was in-hospital death from any cause at 90 days.

RESULTS: The trial was stopped at the second interim analysis for futility. We enrolled 1006 patients early after the onset of moderate-to-severe ARDS (median, 7.6 hours after onset). During the first 48 hours after randomization, 488 of the 501 patients (97.4%) in the intervention group started a continuous infusion of cisatracurium (median duration of infusion, 47.8 hours; median dose, 1807 mg), and 86 of the 505 patients (17.0%) in the control group received a neuromuscular blocking agent (median dose, 38 mg). At 90 days, 213 patients (42.5%) in the intervention group and 216 (42.8%) in the control group had died before hospital discharge (between-group difference, -0.3 percentage points; 95% confidence interval, -6.4 to 5.9; P = 0.93). While in the hospital, patients in the intervention group were less physically active and had more adverse cardiovascular events than patients in the control group. There were no consistent between-group differences in end points assessed at 3, 6, and 12 months.

CONCLUSIONS: Among patients with moderate-to-severe ARDS who were treated with a strategy involving a high PEEP, there was no significant difference in mortality at 90 days between patients who received an early and continuous cisatracurium infusion and those who were treated with a usual-care approach with lighter sedation targets. (Funded by the National Heart, Lung, and Blood Institute; ROSE ClinicalTrials.gov number, NCT02509078.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Moss M, Huang DT, Brower RG, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med. 2019. PMID: 31112383. doi:10.1056/NEJMoa1901686

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。